机构:[1]Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou 510080, China肿瘤治疗中心研究所肺肿瘤科广东省肺癌研究所广东省人民医院[2]Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA[3]Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410018, China[4]Jiangsu Provincial Tumor Hospital, 42 Baiziting, Xuanwu, Nanjing, Jiangsu 210009, China[5]Shanghai Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 Huaihai West Road, Xuhui, Shanghai 200030, China[6]Yunnan Tumor Hospital (The Third Affiliated Hospital of Kunming Medical University), Xingjie Alley, Xishan, Kunming, Yunnan, China[7]Cancer Center, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, China[8]West China Hospital, Sichuan University, 24 South Section 1, Yihuan Road, Chengdu, 610065, China[9]West German Cancer Center, University Duisburg-Essen, Hufelandstraβe 55, Essen 45147, Germany[10]German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen 45147, Germany[11]The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China[12]Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama Prefecture 641- 8509, Japan[13]Princess Alexandra Hospital and Queensland University of Technology, 199 Ipswich Road, Woolloongabba, QLD 4102, Australia[14]McGill University, 845 Rue Sherbrooke O, Montreal, QC H3A 0G4, Canada[15]Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Street 65, Biberach 88400, Germany[16]Boehringer Ingelheim Ltd UK, Ellesfield Avenue, Bracknell, Berkshire RG12 8YS, UK[17]Boehringer Ingelheim GmbH, Binger Street 173, Ingelheim 55216, Germany[18]National Taiwan University Hospital, 7 Chung- Shan South Road, Taipei 100, Taiwan
In the Phase III LUX-Lung 3/6 (LL3/LL6) trials in epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma patients, we evaluated feasibility of EGFR mutation detection using circulating cell-free DNA (cfDNA) and prognostic and predictive utility of cfDNA positivity (cfDNA+).
Paired tumour and blood samples were prospectively collected from randomised patients. Mutations were detected using cfDNA from serum (LL3) or plasma (LL6) by a validated allele-specific quantitative real-time PCR kit.
EGFR mutation detection rates in cfDNA were 28.6% (serum) and 60.5% (plasma). Mutation detection in blood was associated with advanced disease characteristics, including higher performance score, number of metastatic sites and bone/liver metastases, and poorer prognosis. In patients with common EGFR mutations, afatinib improved progression-free survival vs chemotherapy in cfDNA+ (LL3: HR, 0.35; P=0.0009; LL6: HR, 0.25; P<0.0001) and cfDNA- (LL3: HR, 0.46; P<0.0001; LL6: HR, 0.12; P<0.0001) cohorts. A trend towards overall survival benefit with afatinib was observed in cfDNA+ patients.
Plasma cfDNA is a promising alternative to biopsy for EGFR testing. Detectable mutation in blood was associated with more advanced disease and poorer prognosis. Afatinib improved outcomes in EGFR mutation-positive patients regardless of blood mutation status.
基金:
Medical writing assistance, supported financially by Boehringer Ingelheim,
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类|2 区医学
小类|2 区肿瘤学
最新[2023]版:
大类|1 区医学
小类|2 区肿瘤学
第一作者:
第一作者机构:[1]Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou 510080, China
通讯作者:
通讯机构:[1]Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou 510080, China[18]National Taiwan University Hospital, 7 Chung- Shan South Road, Taipei 100, Taiwan
推荐引用方式(GB/T 7714):
Yi-Long Wu ,Lecia V Sequist,Cheng-Ping Hu,et al.EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.[J].British journal of cancer.2017,116(2):175-185.doi:10.1038/bjc.2016.420.
APA:
Yi-Long Wu,,Lecia V Sequist,Cheng-Ping Hu,Jifeng Feng,Shun Lu...&James Chih-Hsin Yang.(2017).EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6..British journal of cancer,116,(2)
MLA:
Yi-Long Wu,,et al."EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.".British journal of cancer 116..2(2017):175-185